Yahoo
Shanghai - Delayed Quote CNY

Jiangsu Hengrui Pharmaceuticals Co.,Ltd (600276.SS)

48.46 -0.16 (-0.33%)
At close: October 30 at 3:00:01 PM GMT+8
Chart Range Bar
Loading chart for 600276.SS
  • Previous Close 48.62
  • Open 48.80
  • Bid 48.46 x --
  • Ask 48.47 x --
  • Day's Range 48.35 - 49.39
  • 52 Week Range 41.89 - 65.83
  • Volume 60,432,595
  • Avg. Volume 72,695,317
  • Market Cap (intraday) 321.639B
  • Beta (5Y Monthly) 0.05
  • PE Ratio (TTM) 36.16
  • EPS (TTM) 1.34
  • Earnings Date --
  • Forward Dividend & Yield 0.20 (0.41%)
  • Ex-Dividend Date May 27, 2026
  • 1y Target Est 71.08

Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.

www.hengrui.com

20,602

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

600276.SS
18.32%
SSE Composite Index (000001.SS)
9.32%

1-Year Return

600276.SS
22.62%
SSE Composite Index (000001.SS)
9.73%

3-Year Return

600276.SS
5.36%
SSE Composite Index (000001.SS)
19.11%

5-Year Return

600276.SS
0.41%
SSE Composite Index (000001.SS)
1.46%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 8.95B
Earnings 2.46B
Profit Margin 27.45%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
2B
4B
6B
8B
24.0%
26.0%
28.0%

Analyst Insights

View More

Analyst Price Targets

50.00
71.08 Average
48.46 Current
111.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    27.04%

  • Return on Assets (ttm)

    7.77%

  • Return on Equity (ttm)

    13.94%

  • Revenue (ttm)

    32.85B

  • Net Income Avi to Common (ttm)

    8.88B

  • Diluted EPS (ttm)

    1.34

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    38.84B

  • Total Debt/Equity (mrq)

    0.10%

  • Levered Free Cash Flow (ttm)

    1.55B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: